SynthesisBMC infectious diseases2023
The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Occupational risk of gastrointestinal Helicobacter pylori infection among medical and dental staff: a systematic review.BMC infectious diseases · 2026Pooled it
- The role of autoimmune gastritis in gastric cancer risk: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Guideline for designing microbiome studies in neoplastic diseases.GeroScience · 2024Guideline
- The effect of supplementing withFrontiers in medicine · 2024Pooled it
- Efficacy of fourteen-day once-daily vonoprazan-based quadruple therapy for Helicobacter pylori in high clarithromycin-resistance regions (ONCE-VONO Trial).Scientific reports · 2025Trial
- AI-assisted endoscopic detection of Helicobacter pylori infection in atrophic gastritis: a multicenter diagnostic study.Surgical endoscopy · 2026Article
- Berberine and Berberine-Derived Compounds as Promising Weapons AgainstPharmaceuticals (Basel, Switzerland) · 2026Review
- Astrovirus infection alters gut microbial communities in a widespread neotropical bat across human-modified landscapes.BMC microbiology · 2026Article
- Efficacy of a family systems theory-based integrated care protocol for children with helicobacter pylori-associated gastritis.Pakistan journal of medical sciences · 2026Article
- Serum levels of immunoglobulins, tumour markers, and chemokines in gastric cancer patients treated with SOX regimen versus oxaliplatin monotherapy.Journal of medical biochemistry · 2026Article
- Source-specific nitrate and nitrite intake and associations with gastric cancer in the Danish Diet, Cancer and Health Cohort.European journal of epidemiology · 2026Article
- The descriptive epidemiology of gastric cancer in Afghanistan: a population-based cancer registry, 2018-2020.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Article
- Molecular detection of Helicobacter pylori in saliva of Sri Lankan adults with periodontitis, gastritis or both conditions.BMC oral health · 2026Article
- Molecular characterization of H. pylori: genetic diversity and vacA s1m1/cagA+ prevalence in Western Algeria.Molecular genetics and genomics : MGG · 2026Article
- Antimicrobial resistance and virulence patterns ofInfectious medicine · 2026Article
- MicroRNAs as Orchestrators of Immune Responses to Bacterial Infection.Microorganisms · 2026Review
- Antimicrobial and Synergistic Activity of Metformin AgainstThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- RACK1 in host immune response to infections: molecular mechanisms and therapeutic potentials.Frontiers in immunology · 2026Review
- Immunoinformatics-Based Multi-Epitope Vaccine Targeting Helicobacter Pylori.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori is a gastrointestinal pathogen that infects around half of the world's population. H. pylori infection is the most severe known risk factor for gastric cancer (GC), which is the second highest cause of cancer-related deaths globally. We conducted a systematic review and meta-analysis to assess the global prevalence of GC in H. pylori-infected individuals.
methodsWe performed a systematic search of the PubMed, Web of Science, and Embase databases for studies of the prevalence of GC in H. pylori-infected individuals published from 1 January 2011 to 20 April 2021. Metaprop package were used to calculate the pooled prevalence with 95% confidence interval. Random-effects model was applied to estimate the pooled prevalence. We also quantified it with the I
resultsAmong 17,438 reports screened, we assessed 1053 full-text articles for eligibility; 149 were included in the final analysis, comprising data from 32 countries. The highest and lowest prevalence was observed in America (pooled prevalence: 18.06%; 95% CI: 16.48 - 19.63; I
conclusionsH. pylori infection in GC patients varied between regions in this systematic review and meta-analysis. We observed that large amounts of GCs in developed countries are associated with H. pylori. Using these data, regional initiatives can be taken to prevent and eradicate H. pylori worldwide, thus reducing its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.